Recently, Fortune magazine, in collaboration with Well Equity Partners, released a list of key health enterprises to focus on in 2025. ASRock Medical (Suzhou) Co., Ltd., along with several Fortune 500 and breakthrough companies, was selected, confirming the company's innovation strength and global market potential.
The core correlation between heart failure and overall health: the key breakthrough point of health and longevity goals
The core of big health is "health+longevity", and heart failure is the key health issue that affects this goal - it is not only a high-risk disease for the elderly, but also directly related to the core demand of "living long and well". The relationship between the two is reflected in three core levels:
• Heart failure is a major health burden for the elderly population, directly impacting their 'healthy lifespan'. With the growth of age, the heart function naturally declines, and the incidence rate of heart failure increases significantly, which is often accompanied by a variety of complications. Once it happens, it is easy to lead to the inability to take care of oneself, repeated hospitalization, and even life-threatening, becoming an important obstacle to "healthy life". The concept of big health provides a complete solution for the treatment of heart failure.
• Big Health emphasizes the full chain management from treatment to prevention, from severe illness to daily life, rather than simply treating diseases - this is highly in line with the management needs of heart failure: it is necessary to control acute attacks through effective medical means, delay disease progression through long-term management, and ensure that patients maintain their quality of life while suffering from illness.
• The technological breakthroughs in heart failure treatment and global accessibility are the core manifestations of the implementation of big health. The essence of big health is to bring high-quality health services to more people. In the past, key equipment for heart failure treatment relied heavily on imports, with high prices and limited adaptability. The technological breakthroughs of Chinese enterprises not only reduce domestic medical costs and improve accessibility, but also lay the foundation for technology to go global and serve the health and longevity needs worldwide.
Focusing on the essential needs of heart failure, constructing a matrix of artificial heart products
Starting from the clinical needs of heart failure, Xinqing Medical has built a multi organ life support platform and created a product system that not only meets the pain points of domestic clinical practice, but also has global competitive potential
• In vitro fully magnetic levitation artificial heart MoyoAssist ® 【1】：Suitable for patients with cardiogenic shock, it can provide 30 days of life support to assist patients in transitioning to endpoint therapies such as cardiac function recovery and heart transplantation. Its blood compatibility meets the industry's "gold standard", supports multi chamber catheterization, and is suitable for various clinical scenarios; In clinical applications, the patient survival rate has increased from 33% to 60%. This product was approved for market by the National Medical Products Administration (NMPA) in April 2024, and its ECMO adaptation scope will be further expanded in 2025, and it will be included in the Jiangsu Province medical insurance catalog.
• Minimally invasive artificial heart NyokAssist ® 【2】：Suitable for high-risk PCI intraoperative protection, supporting a duration of 6 hours. Its 9Fr intervention size reduces vascular trauma by 40% compared to similar products, and the probability of vascular complications and bleeding is reduced by 3-4 times; By combining low-speed flow field optimization, the risk of hemolysis is lower than that of similar international products; External motor design helps reduce patient usage costs. This product has obtained the breakthrough medical device certification from the US FDA and the "green channel" qualification for China's innovative medical device review. The results of its SAVE-PCI multicenter randomized controlled clinical trial were announced at the TCT 2025 Late Breaking Clinical Science session, and the data showed good performance.
•The new generation portable ECMO system BreathMo ® 【2】：Suitable for patients with heart failure combined with respiratory failure, it can provide 14 days of life support and has received key support from the Jiangsu Province Science and Technology Achievement Transformation Special Fund. Its pressure drop is ≤ 40mmHg, and the performance of the artificial lung is closer to the physiological state; In clinical applications, the patient survival rate has increased from 20% to 70%, and no major adverse events related to the device have occurred. During the 2023 Hangzhou Asian Games, the system was installed in the "5G emergency unit" to provide security for the event.
The company's multiple products have covered various scenarios such as postoperative low cardiac output, heart transplant bridging, and acute cardiogenic shock. In high-risk and complex surgical treatment, they can effectively stabilize intraoperative circulation, ensure surgical safety, and help patients recover their cardiac function quickly after surgery.
Dual engines of China and the United States, coordinated development of localization foundation and globalization layout
The core competitiveness of Xinqing Medical comes from continuous technological research and interdisciplinary integration. Founder Dr. Xu Boling holds a PhD in Electrical Engineering from the University of Cambridge in the UK and a PhD in Medical Engineering from RWTH Aachen University in Germany. For 20 years, she has been deeply involved in the field of artificial heart design and system evaluation, laying a professional foundation for the company's technological layout.
The enterprise practices the "combination of medicine and engineering, joint research and development" model, builds interdisciplinary innovation platforms, and breaks through multiple core technologies: it not only fills the technical gaps in related fields in China, but also reduces dependence on imported equipment; Through technological optimization, we have also provided more efficient and reliable life support solutions for the global healthcare market. The industry recognition of its technological achievements continues to rise. With its continuous research and development achievements and clinical application performance in the field of artificial heart and life support technology, the company has successfully been shortlisted for the "Best Start Up" award at the Prix Galien. This award is widely regarded as one of the most influential honors in the global life science and medical technology field, aiming to recognize scientific innovations that can significantly improve human health. This nomination is not only an authoritative recognition of the company's technological innovation and clinical value, but also further strengthens its industry influence in the global medical device field.
In terms of intellectual property management, the company has established a sound system and has applied for over 400 patents so far. In the past two years, nearly 200 new patents have been applied for at home and abroad. At the same time, it has completed international patent layout in major countries such as the United States and Europe, providing intellectual property reserves and strategic support for international development.
Focusing on the layout of "dual engines of China and the United States", enterprises are promoting technology industrialization and clinical implementation in China while accelerating the expansion of overseas markets: by October 2025, NyokAssist ® The Investigator Meeting was held in the United States, where cardiovascular experts from China, the United States, and Hong Kong, China gathered to have in-depth exchanges on the upcoming international multicenter clinical trial and reached consensus on research pathways, team collaboration mechanisms, and other issues.
Based on clinical needs, serving global health
The Fortune list focuses on the core demand of "health+longevity", and the development path of ASRock Medical is deeply aligned with it. Through measures such as technology industrialization, medical insurance inclusion, and minimally invasive design, enterprises have not only solved the problem of "treating heart failure well", but also achieved the goal of "affordable", effectively serving the life and health needs of people around the world.
Standing at the new starting point of "moving from China to the world", Xinqing Medical will continue to deepen the multi organ life support track: break through core technologies with deep research and development, optimize product experience with clinical temperature, accelerate product iteration and clinical transformation with innovation, promote the parallel development of localization and internationalization of key life support equipment, and bring accessible and reliable life support solutions to more patients around the world.